Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Can a drug that lowers “bad” cholesterol — and also raises the so-called “good cholesterol,” HDL — help to prevent ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis worsening. The combination was associated with a worsening fasting lipid and ...

There are a number of emerging therapies in development for lowering lipoprotein(a), and later-stage trials are underway.Interest continues to grow in lipoprotein(a), commonly known as Lp(a), both as ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine ...

Key Points Merck aims to boost its business by buying Verona Pharma for $10 billion.Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.With the stock valued at ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multiyear effort comes as Merck ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by the end of 2027.